Product Description
Valdecoxib is a non-steroidal anti-inflammatory drug. Nonsteroidal anti-inflammatory drugs (also called NSAIDs) are used to relieve some symptoms caused by arthritis (rheumatism), such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not cure arthritis and will help you only as long as you continue to take it. It may also be used to treat pain associated with menstrual periods. (Sourced from: https://www.mayoclinic.org/drugs-supplements/valdecoxib-oral-route/description/drg-20066654)
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Chile | Colombia | European Medicines Agency | Germany | Greece | Hungary | India | Ireland | Italy | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | South Africa | Sweden | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Pain, Postoperative|Hyperalgesia|Arthritis, Rheumatoid|Nociceptive Pain|Inflammation|Low Back Pain|Pain Unspecified|Osteoarthritis, Knee|Acute Pain|Ankle Injuries
Phase 3: Pharyngitis|Hallux Valgus|Pain Unspecified|Bunion|Pain, Postoperative|Pancreatitis|Toothache|Osteoarthritis, Knee|Morphine Dependence|Acute Pain
Phase 2: Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IIG Pfizer(PJK) | P4 |
Completed |
Hyperalgesia |
2006-04-01 |
|
| GE-ERCP-AP/2006 | P3 |
Terminated |
Pancreatitis |
2005-09-01 |
|
| 2004-001713-34 | P4 |
Terminated |
Osteoarthritis, Knee |
2005-03-01 |
|
| A3471018 | P4 |
Completed |
Arthritis, Rheumatoid |
2005-01-01 |